Gossamer Bio (NASDAQ:GOSS) Lowered to “Sell” Rating by Wall Street Zen

by · The Markets Daily

Wall Street Zen lowered shares of Gossamer Bio (NASDAQ:GOSS – Free Report) from a hold rating to a sell rating in a report issued on Sunday morning,Wall Street Zen reports.

GOSS has been the topic of a number of other research reports. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Tuesday, July 28th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Finally, Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $256.00.

Read Our Latest Stock Report on GOSS

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $10.73 on Friday. Gossamer Bio has a fifty-two week low of $9.10 and a fifty-two week high of $309.60. The stock has a market capitalization of $31.44 million, a PE ratio of -0.19 and a beta of 2.00. The business’s 50-day simple moving average is $13.11 and its 200-day simple moving average is $20.38.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Corient Private Wealth LP lifted its stake in Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after acquiring an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC grew its stake in shares of Gossamer Bio by 1,289.4% during the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after acquiring an additional 1,469,175 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Gossamer Bio during the 2nd quarter worth approximately $65,000. Hhlr Advisors LTD. acquired a new stake in shares of Gossamer Bio in the second quarter valued at approximately $819,000. Finally, ARCH Venture Management LLC acquired a new stake in shares of Gossamer Bio in the second quarter valued at approximately $1,326,004. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.

Featured Stories